2018
DOI: 10.1093/cid/ciy260
|View full text |Cite
|
Sign up to set email alerts
|

Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
39
1
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 57 publications
(45 citation statements)
references
References 10 publications
4
39
1
1
Order By: Relevance
“…31,82,83 and isavuconazole. 82,84,85 Overall, rates are generally low with voriconazole and posaconazole (range 3.1%-6.5%) but may be higher with isavucanazole with rates of bIFI 13% in one study 86 and 8.3% in another. 87 Several studies have described antifungal resistance as a driver of bIFI in patients with haematologic malignancies.…”
Section: B Re Ak Throug H Inva S Ive Fung Al Infec Ti On S In Patiementioning
confidence: 96%
“…31,82,83 and isavuconazole. 82,84,85 Overall, rates are generally low with voriconazole and posaconazole (range 3.1%-6.5%) but may be higher with isavucanazole with rates of bIFI 13% in one study 86 and 8.3% in another. 87 Several studies have described antifungal resistance as a driver of bIFI in patients with haematologic malignancies.…”
Section: B Re Ak Throug H Inva S Ive Fung Al Infec Ti On S In Patiementioning
confidence: 96%
“…Of major concern are recently emerging studies reporting cases of breakthrough mucormycosis and other IFIs in patients receiving isavuconazole as prophylaxis or treatment [ 65 , 66 ]. In a trial of intravenous isavuconazole prophylaxis in acute myeloid leukemia patients, 18% (2/11) of patients had possible breakthrough fungal infection [ 67 ].…”
Section: Treatmentmentioning
confidence: 99%
“…Half of the microbiologically documented lung infections in that study were caused by Mucorales [ 65 ]. In another study, five cases of breakthrough IFIs have been reported among patients with hematological malignancies receiving isavuconazole as prophylaxis [ 66 ]. The reported fungal species that caused breakthrough infection included Aspergillus spp., Mucorales , non-albicans Candida spp., and Scedosporium apiospermum .…”
Section: Treatmentmentioning
confidence: 99%
“…Breakthrough PM infections while on posaconazole prophylaxis has been increasingly reported . While none of our patients were on isavuconazole prophylaxis, failures of isavuconazole prophylaxis to prevent PM are also being increasingly recognised . It is not clear if these breakthrough PM infections are due to antifungal resistance, antifungal pharmacokinetics, the host's net state of immune dysfunction, or a combination of these factors.…”
Section: Discussionmentioning
confidence: 86%